US Cases/Year
~15,000
Most common and most lethal primary brain tumor in adults.[1]
What Is It
What GBM is, why it's different, and why it demands a different palliative care framework than any other cancer.
Median OS (Stupp)
14–16 mo
Surgery + RT + temozolomide. Without treatment: 3–4 months.[2]
5-Year Survival
~6%
IDH-wildtype GBM. IDH-mutant has meaningfully better prognosis.[1]
Seizure Prevalence
25–40%
Lifetime risk in GBM patients; higher in temporal and frontal lobe tumors.[3]
Glioblastoma (GBM) is the most common and most lethal primary malignant brain tumor in adults — WHO Grade IV. It accounts for approximately 50% of all malignant primary brain tumors and approximately 15,000 new cases per year in the United States. The standard of care (Stupp protocol: maximal safe surgical resection followed by concurrent chemoradiation with temozolomide) yields a median overall survival of 14–16 months. Without treatment, median survival is 3–4 months. Five-year survival is approximately 6% for IDH-wildtype tumors.[1][2]
Molecular Markers That Matter in Prognosis Conversations: IDH status: IDH-wildtype = most common (~90%), most aggressive. IDH-mutant glioma behaves significantly better — if your patient's report says IDH-mutant, recalibrate prognosis upward. MGMT promoter methylation: Present in ~40–50% of GBM. Predicts better response to temozolomide. Patients whose tumor has MGMT methylation live longer on average. Know which bucket your patient is in before prognostic conversations.[6]
🧠 Why GBM Is Different in Palliative Care
GBM is not just a fatal cancer — it is a progressive loss of the self. Personality, memory, language, judgment, and emotional regulation are stripped away before the body fully fails. The person changes before they die. This demands a palliative care framework that addresses grief before death: the family is often mourning someone who is still breathing.
Median Age at Diagnosis
64 yrs
Men slightly more affected than women. No modifiable risk factors established except ionizing radiation.[1]
Dx → Hospice Enrollment
8–12 mo
Most patients have already completed or declined treatment by the time of hospice referral.[4]
OS After Recurrence
6–9 mo
Median OS after first recurrence with available salvage therapy.[5]
"The cruelest thing about GBM is that families lose their person twice. The first time when the frontal lobe goes — when he stops being funny, stops filtering, stops seeming like himself. The second time when he stops breathing. The grief between those two moments is the part nobody prepared them for. I've sat across from wives, daughters, sons who looked at me and said, 'I know he's still here, but I've been mourning him for months.' That's not unusual. That's GBM. Your job as a clinician isn't just to manage symptoms — it's to acknowledge that the grief started early, and that it's legitimate, and that caring for who remains is still caring for him."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, molecular profiling, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Diagnostic Workup
- MRI with gadolinium contrast: Gold standard — ring-enhancing lesion with central necrosis is the classic GBM pattern[45]
- Stereotactic biopsy or surgical resection: Tissue required for definitive diagnosis — WHO Grade IV histopathology
- IDH1/IDH2 mutation status: IDH-wildtype = GBM, worse prognosis; IDH-mutant = better prognosis, often younger patients[46]
- MGMT methylation status: Predicts temozolomide benefit — methylated MGMT has better response and survival[6]
- EGFR amplification, TERT promoter mutation: Additional molecular markers informing prognosis
- 1p/19q codeletion: Distinguishes from oligodendroglioma — if present, reclassify
What to Look for in Hospice Records
- IDH and MGMT status: Predicts trajectory and residual treatment options
- Prior surgery extent: Gross total resection vs. biopsy only — affects trajectory
- Prior radiation dose and fields: Re-irradiation possible at recurrence — know if done
- Current AED medication and seizure history: Frequency, type, last event
- Current dexamethasone dose and duration: Critical — steroid dependency and taper planning is one of the most important clinical issues at hospice enrollment
- Recurrence treatment history: Bevacizumab, lomustine, temozolomide re-challenge — know what has been used
- Tumor location: Frontal = personality/executive function; temporal = language/memory; parietal = spatial/sensory; occipital = vision; dominant hemisphere involvement affects communication capacity
💡 Neurological Grading in GBM
KPS (Karnofsky Performance Scale) is the primary functional tool in neuro-oncology. Know the patient's current KPS. KPS <70 is an independent predictor of poor OS. Both KPS and ECOG are validated prognostic tools — the Palliative Prognostic Index (PPI) also shows validity in brain tumor patients for short-term prognosis.[9]
Causes & Risk Factors
GBM has very few established risk factors — this is clinically important and must be addressed explicitly because patients and families almost universally ask.
Established Risk Factors
- Prior therapeutic ionizing radiation to the head: The only established environmental risk factor — most commonly from childhood cancer treatment; latency 10–20 years
- Rare hereditary syndromes: Li-Fraumeni/TP53, neurofibromatosis type 1, Lynch syndrome — together account for <5% of GBM
Not Established Risk Factors
- Cell phones: Not an established risk factor despite popular belief
- Electromagnetic fields: No causal association established
- Head trauma, stress, diet, alcohol: None are established risk factors for GBM
⚕ Disparity Note
GBM incidence is slightly higher in white Americans than Black Americans — the reverse of most cancers. This may reflect differential access to MRI and thus detection bias as much as true incidence differences. No major racial mortality disparity in GBM, though access to high-volume neuro-oncology centers differs significantly.[1]
❤️ For Families: "Why Did This Happen?"
GBM develops from acquired somatic mutations. There is nothing the patient did that caused this. There is no known behavioral, dietary, or environmental exposure that causes GBM in most patients. This conversation must happen explicitly at enrollment — families carry enormous guilt and need to be told directly that it is misplaced.
Treatments & Procedures
What disease-directed treatments this patient may have received or may still be receiving. Every prior treatment leaves a neurological footprint — know what was done, when, and what changed after each intervention.
Standard treatment trajectory in GBM: Maximal safe surgical resection → concurrent chemoradiation (60 Gy over 6 weeks + temozolomide) → adjuvant temozolomide cycles. At recurrence: bevacizumab, lomustine, re-irradiation in selected patients, or clinical trial enrollment. Each intervention leaves a neurological footprint that the hospice team must understand.[2]
Surgery & Radiation
- Maximal safe resection: Extent of resection correlates with survival; know if gross total vs. subtotal vs. biopsy only; surgical cavity is the origin of recurrence[43]
- Standard fractionated RT: 60 Gy over 6 weeks; hypofractionated RT for elderly/poor KPS — 40 Gy over 3 weeks; know prior dose and fields
- Tumor treating fields (Optune): Worn on scalp; modest OS benefit in newly diagnosed; burdensome device; know if patient has used
Systemic Therapy & Steroids
- Temozolomide: Concurrent with RT and adjuvant — Stupp protocol; MGMT-methylated tumors benefit most[6]
- Bevacizumab (anti-VEGF): Approved for recurrent GBM; reduces edema and steroid requirement but does not extend OS; important for symptom management[23]
- Lomustine (CCNU): Recurrent GBM; oral alkylating agent
- Dexamethasone: Not a treatment but an essential symptom management tool; reduces cerebral edema; steroid dependency develops and taper planning is critical[18]
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.
The goals-of-care conversation window in GBM is narrow and closes as cognition declines — if the patient has decision-making capacity today, have the full goals-of-care conversation today. Do not wait for a "better time." There may not be one.[7]
- 01IDH-mutant GBM with adequate KPS (≥70): Meaningfully better response to standard therapy and longer trajectory. Continuing treatment is well-supported.[46]
- 02MGMT-methylated GBM: Temozolomide benefit is clearest here; worth continuing if tolerating well and KPS adequate. The molecular profile supports continued therapy.[6]
- 03Bevacizumab for recurrent GBM with KPS ≥60: Reduces edema, reduces steroid requirement, improves functional quality of life even if OS benefit is modest. Hospice-compatible discussion.[23]
- 04Re-irradiation in selected patients: Small volume, good KPS, long interval from prior RT — discuss with radiation oncology. Younger patients (<60) with accessible tumor location benefit most.
- 05Patient goals explicitly include life-prolongation: A well-informed patient who understands prognosis and chooses active treatment should receive it without judgment. KPS ≥60 and caregiver support adequate for treatment burden.
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
The unique GBM challenge: the patient may lose capacity to participate in goals-of-care decisions before the family is ready to make them. Advance care planning must happen early — this is the most time-sensitive goals conversation in all of hospice oncology.[7][34]
- 01KPS <60: No evidence of survival benefit from further systemic therapy; treatment burden exceeds potential benefit.[8]
- 02IDH-wildtype GBM at recurrence post-Stupp: Median OS 6–9 months from recurrence regardless of salvage — be honest about what additional treatment offers.[5]
- 03Progression through bevacizumab: Post-bevacizumab progression carries median OS of 3–4 months; salvage options are very limited.[48]
- 04Cognitive decline eliminating informed consent capacity: Patient can no longer participate in treatment decisions — shift to surrogate decision-maker and comfort-focused goals.
- 05Seizures refractory to ≥2 antiepileptics: Refractory epilepsy in GBM signals advanced disease; focus shifts to seizure comfort management.[3]
- 06Steroid dependency with side effects exceeding benefits: Cushingoid state, proximal myopathy, hyperglycemia, psychiatric effects — steroid taper planning becomes the primary clinical challenge.[18]
- 07Estimated survival <3 months: Family and patient goals shift to quality time, home, and presence. Hospice enrollment is appropriate, beneficial, and guideline-supported.
📋 Clinician Note
The patient may lose capacity to participate in goals-of-care decisions before the family is ready to make them. In GBM, the conversation must happen early and be revisited at every visit. Document the transition from patient-directed to surrogate-directed in real time. This is not optional — it is the defining communication challenge of GBM hospice care.
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Corticosteroid Optimization
Grade ADexamethasone 4–16 mg/day · Individualized taper protocol
Dexamethasone is the most important symptom management tool in GBM. Evidence-based tapering protocols reduce side effects while maintaining edema control. The goal is the lowest effective dose, not elimination if symptoms recur. Taper by 25–50% every 3–5 days; never abruptly discontinue after >2 weeks of use.[18][53]
Antiepileptic Optimization
Grade ALevetiracetam 500–1500 mg BID · Lacosamide for refractory
Bevacizumab for Edema & Steroid-Sparing
Grade BBevacizumab per neuro-oncology protocol
Reduces dexamethasone requirement significantly; improves functional quality of life. Evidence for survival benefit is mixed, but symptom and QoL data support its consideration when steroid side effects are intolerable. Hospice-compatible discussion with neuro-oncology.[23]
Mind-Body Therapies for Caregiver Support
Grade BMBSR programs · Structured caregiver support groups
Music & Reminiscence Therapy
Grade CIndividualized music playlists · Life narrative exercises
Maintains connection and identity when language and executive function decline. Particularly meaningful when personality change has alienated the patient from their family's experience of who they were. Music reaches parts of the brain that language no longer can — this is neuroscience, not sentiment.
Acupuncture for Pain & Headache
Grade CIndividualized acupuncture protocols
Limited GBM-specific data; general oncology evidence for pain and nausea. Safe if no coagulopathy from steroids. May reduce headache severity and analgesic requirement as adjunct to pharmacotherapy.
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to GBM. Patients will use supplements — this section helps you have the right conversation.
"Patients are going to use supplements whether we ask or not. The conversation is: 'I want to know what you're taking — not to judge you, but because some of these interact with your seizure medications and steroids.' In GBM specifically, anything that affects seizure threshold is the conversation you must have. Say it plainly. Most of the time they're relieved someone asked."
— Waldo, NP
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Cannabis / CBD | Grade C | Individualized; sublingual preferred | CBD may have anticonvulsant properties; appetite and anxiety benefit; some preclinical anti-proliferative signal | THC can lower seizure threshold — use with extreme caution in seizure patients. CBD inhibits CYP3A4 — may raise dexamethasone levels. Discuss with neuro-oncology before recommending. |
| Melatonin | Grade C | 1–5 mg QHS | Sleep benefit is real and meaningful given steroid-related insomnia; some GBM preclinical anti-proliferative signal | Dexamethasone suppresses endogenous melatonin. Safe at standard doses. No seizure threshold concerns. Take 2+ hours after evening steroid dose. |
| Ginger | Grade B | 500–1000 mg/day in divided doses | Nausea from chemotherapy and steroids; well-studied for CINV | Antiplatelet caution at medicinal doses in post-craniotomy patients. No seizure threshold concerns. Minimal drug interactions. |
| Omega-3 Fatty Acids | Grade C | ≤3 g/day EPA+DHA | Anti-inflammatory signal; may reduce steroid dose requirement marginally; general cachexia management | Avoid high doses in patients on anticoagulation or recent craniotomy. Liquid formulation preferred when swallowing compromised. Generally safe. |
| Curcumin / Turmeric | Grade C | 500–2000 mg/day | Anti-inflammatory; some preclinical GBM signal; possible preclinical anti-epileptic properties | CYP3A4 interactions — monitor dexamethasone response. Antiplatelet caution at >2 g/day in post-craniotomy patients. Poor bioavailability unless formulated with piperine. |
🚫 Avoid in GBM
- St. John's Wort: CYP3A4 inducer — destroys temozolomide, lomustine, and bevacizumab blood levels; significantly reduces dexamethasone levels. Serious and well-documented interaction. Absolutely contraindicated.
- High-dose antioxidants (Vitamins C and E at high doses): Theoretical interference with radiation and temozolomide oxidative mechanism if still receiving treatment. Avoid during active treatment. Vitamin E >400 IU also carries antiplatelet risk post-craniotomy.
- Cannabis with high THC content in seizure patients: THC can lower seizure threshold — the most dangerous supplement interaction in GBM specifically. Any cannabis use must be discussed with the neuro-oncology team.
- Ginkgo biloba: Antiplatelet — compounded bleeding risk in patients on dexamethasone with GI mucosal vulnerability. High doses may also lower seizure threshold. Avoid in patients with active seizure history or recent neurosurgery.
- Any herb with significant seizure threshold effects: This is the defining contraindication category in GBM that does not exist in other diagnoses. Valerian, kava, high-dose ashwagandha — all require extreme caution or avoidance.
Timeline Guide
A guide, not a prediction. Every patient's trajectory is shaped by IDH status, MGMT methylation, treatment response, tumor location, and age at diagnosis.
IDH-wildtype GBM follows this general trajectory. IDH-mutant patients have meaningfully longer timelines at every phase. MGMT-methylated tumors respond better to temozolomide and may extend the early phases. Pseudoprogression on MRI (treatment effect vs. true progression) can cause confusion and premature decisions — distinguish carefully.[2][5]
YRS–
MOS
MOS
Post-Surgical / Concurrent Chemoradiation (Stupp)
- Recovering from surgery; fatigue from radiation; temozolomide adjuvant cycles; MRI surveillance every 2 months
- KPS typically 70–90 in this phase; personality and cognition relatively intact
- Pseudoprogression possible on MRI — treatment effect vs. true progression can cause confusion and premature decisions
- This phase averages 6–12 months in IDH-wildtype GBM; prognostic conversations must start here — before the window closes
MOS–
1 YR
1 YR
First Recurrence — The Critical Window
- Confirmed on MRI — true progression distinguished from pseudoprogression; bevacizumab initiated; possible re-irradiation or lomustine
- KPS declining; seizure frequency may change; personality changes emerging or worsening; steroid dependency established
- This is the cognitive window for goals-of-care conversations — the last phase where most patients retain decision-making capacity
- Caregiver stress escalating; palliative care integration critical and often delayed — this is the window[7]
WKS–
MOS
MOS
Second Recurrence / Bevacizumab Failure — Hospice Transition
- KPS declining to 50–60; increasing somnolence; language difficulty if dominant hemisphere
- Behavioral disinhibition if frontal; incontinence developing; eating becoming difficult (dysphagia)
- Hospice enrollment most appropriate at this transition; surrogate increasingly primary decision-maker
- Steroid taper conversation must be initiated; comfort kit preparation[4]
DAYS–
WKS
WKS
Active Dying — Pre-Active Phase
- Profound somnolence; minimal purposeful interaction; seizure risk still present but may decrease as tumor suppresses cortical activity
- Steroid taper in progress or complete; dysphagia to medications — convert to SQ or rectal route
- Incontinence; possible terminal restlessness if not from steroid withdrawal
- All medications reviewed for comfort contribution only[31]
HRS–
DAYS
DAYS
Final Hours
- Unresponsive or minimally responsive; periodic breathing; mottling
- Possible terminal seizure — have midazolam drawn and at bedside
- Family at bedside; auditory awareness may persist — speak to the patient
- Presence is the clinical priority; music from their life reaches parts of the brain that language no longer can[39]
Medications to Anticipate
Symptom-targeted pharmacology for GBM. What to have in the comfort kit, what to titrate first, and what the evidence supports.
GBM medication management is dominated by three systems: seizure control (levetiracetam), edema control (dexamethasone), and comfort (opioids, midazolam, haloperidol). The interplay between these — particularly the steroid–seizure–cognition triad — defines every medication decision.[10][18]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Levetiracetam | AED / Seizure prophylaxis + treatment | 500–1500 mg BID | First-line AED in GBM. No hepatic metabolism, no drug interactions. SQ route not available — convert to rectal valproate or buccal/intranasal midazolam as swallowing fails. Watch for "Keppra rage" — irritability, aggression.[12] |
| Dexamethasone | Corticosteroid / Cerebral edema | 4–16 mg daily in divided doses | Most important drug in GBM symptom management. Taper planning is a primary clinical task at hospice enrollment. ⚠ Do NOT abruptly discontinue — rebound edema causes acute neurological crisis.[18] |
| Midazolam | Benzodiazepine / Seizure emergency + terminal agitation | 5–10 mg SQ/IM/buccal for active seizure; 2.5–5 mg SQ PRN for agitation | MUST be in comfort kit drawn and labeled from day one of hospice enrollment. A breakthrough seizure at home without emergency medication is a family trauma and a clinical failure.[16] |
| Morphine or Oxycodone | Opioid / Headache + pain | Morphine 2.5–5 mg PO/SQ q4h; Oxycodone 5 mg PO q4h PRN | Cerebral edema causes severe headache; opioids are appropriate. ⚠ Avoid tramadol — proconvulsant, absolutely contraindicated in GBM. If patient arrives on tramadol, convert immediately.[29] |
| Haloperidol | Antipsychotic / Agitation + delirium | 0.5–1 mg SQ BID | For behavioral disinhibition from frontal lobe involvement. Avoid high-dose antipsychotics in GBM. Risperidone 0.5 mg as alternative. Quetiapine 12.5–25 mg for agitation/sundowning. |
| Lorazepam | Benzodiazepine / Anxiety | 0.5–1 mg PO/SQ q4–6h PRN | Adjunct to midazolam for seizure management. ⚠ May worsen confusion and disinhibition in GBM — use as adjunct only. |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h | Reduces secretions without CNS effects. Preferred over hyoscine in conscious patients. |
| Pantoprazole | PPI / GI protection from dexamethasone | 40 mg PO/IV daily | Essential while on steroids — continue until steroid taper complete. Dexamethasone plus NSAIDs = high GI bleeding risk. |
| Bevacizumab (discussion) | Anti-VEGF / Edema reduction | Per neuro-oncology protocol | Individualize — may reduce edema and steroid requirement even in hospice. Discuss continuation with neuro-oncology team.[23] |
🌿 Symptom Management Decision Tree
Evidence-based · Hospice-adaptedSelect a symptom below to begin
What is the primary symptom to address?
🚨 Comfort Kit Must-Haves for GBM
Midazolam drawn, labeled, and at the bedside from day one. A breakthrough seizure at home without emergency medication available is a family trauma and a clinical failure. Additionally — tramadol is absolutely contraindicated in GBM due to proconvulsant effects; if patient arrives on tramadol from prior provider, convert to oxycodone IR immediately. Document this in the care plan.[29]
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.
1
The goals-of-care window closes as cognition declines
If the patient has capacity today, have the full goals-of-care conversation today. Do not schedule it for next week. In GBM, next week may be too late. The cognitive window is typically Phase 2 — most clinicians wait until Phase 3 or 4. By then, the patient may no longer be able to tell you what matters to them.[7]
2
Steroid taper is a primary clinical task at hospice enrollment
There is no standard taper; individualize based on neurological status. Abrupt discontinuation causes rebound edema and acute crisis. Too slow a taper causes Cushingoid state, myopathy, hyperglycemia, and psychiatric effects. The right dose is the lowest dose that keeps the patient comfortable. Check it every visit.[18]
3
Tramadol is absolutely contraindicated in GBM
Proconvulsant effects are well-documented. If you inherit a GBM patient on tramadol, convert to oxycodone IR immediately and document why. This is not a debatable clinical point. Switch to oxycodone 5 mg q4h PRN as standard alternative.[29]
4
Personality change is not the patient being difficult
Frontal lobe disinhibition, temporal lobe irritability, and steroid-induced psychiatric effects create behavioral changes that families experience as loss of the person they knew. Name it, explain it, and prepare the family before it becomes a crisis. The family who was briefed is not destroyed by it; the family who was not is.[35]
5
Anticipatory grief in GBM begins at diagnosis
Families are grieving the personality changes, the cognitive losses, and the future all simultaneously. The hospice team must address this grief actively, not wait for death to make it official. Use the term "ambiguous loss" — the person is physically present but psychologically absent. Validate this grief explicitly.[32]
"I've sat across from a daughter — she was maybe 45 — and she asked me, 'Why does my dad keep saying these things? Why is he so mean? He was never like this.' And I had to explain to her that the frontal lobe controls filtering. That what he says now isn't coming from who he is — it's coming from where the tumor is. The love underneath is still there. It's just locked in a room that doesn't have a key anymore. That metaphor isn't scientific. But it's the thing that makes people cry-nod instead of just cry. And cry-nod means they heard you."
— Waldo, NP · Terminal2
"The most important conversation you'll ever have with a GBM patient has to happen in month three. Not month eleven. Most clinicians wait until month ten to try — and by then, the person who could've told you what they wanted is already not fully there. The cognitive window is not theoretical. I've watched it close in real time. You're sitting there thinking 'we still have time' — and then you don't. The urgency here isn't about being morbid. It's about making sure the patient's own voice gets to shape what happens to them. That window opens in Phase 2 and shuts faster than you expect. Walk through it."
— Waldo, NP · Terminal2
Psychosocial & Spiritual Care
Anticipatory grief, ambiguous loss, caregiver identity crisis, and the spiritual dimension of cognitive loss. The symptom burden you can't see on a vitals sheet.
Anticipatory grief and ambiguous loss — families grieve the personality, the cognition, and the relationship while the patient is still alive. This is one of the most psychologically devastating aspects of GBM and it is underaddressed. Use the term "ambiguous loss" — the person is physically present but psychologically absent. Validate this grief explicitly. It is not disloyal. It is inevitable.[32]
The decision-making window — GBM erodes capacity progressively and unpredictably. Advance care planning must happen as early as possible. The hospice team must assess decision-making capacity at every visit and document it. When capacity is lost, the family becomes the surrogate decision-maker often without preparation.[7]
Psychological Distress Screening
Caregiver Identity Loss
Grade BThe spouse or partner of a GBM patient is caring for someone whose personality has changed. The relationship itself has changed. The caregiver is grieving their partner while simultaneously providing 24-hour care. Burnout is not just likely — it is statistically inevitable without support. Assess and address at every visit.[32][33]
Existential Distress Around Personality Change
Grade BPatients who retain awareness of their personality changes experience profound shame, grief, and fear. Address it directly: "the brain is sick, not you" is a clinical statement, not a platitude. Dignity therapy and structured life narrative reduce suffering and increase sense of meaning.[35]
Spiritual Assessment
Spiritual dimension of cognitive loss: For patients of faith, the loss of the ability to pray, read scripture, worship, or connect with their faith community is a specific spiritual wound. Chaplain involvement is essential and should happen at enrollment — not at crisis. Use the FICA framework: Faith/beliefs, Importance, Community, Address.[41]
Goals-of-care framing specific to GBM: "Staying home, staying myself as long as possible, and not dying in a hospital" is almost universally the operative goal. Build every clinical decision around protecting those three things.
Clinical Pearl
"What gives you strength during this time?" opens spiritual conversation without assuming any tradition. For GBM patients with intact awareness, the spiritual question is often about legacy — what will remain of me when the person I was is already fading? Your job is to create space for that question to be asked and answered.
Goals-of-Care Communication
Opening the Conversation
- "What is your understanding of where things stand with your illness?"
- "What are you hoping for?" — surfaces values, not just preferences
- "What are you most afraid of?" — identifies what goals-of-care planning must address
- "I want to make sure we know what matters most to you, while we can hear it directly from you."[42]
Suicidal Ideation & Hastened Death
- Passive wish for death ("I'm ready to go") — common and often existentially appropriate
- Active suicidal ideation with plan — requires immediate psychiatric engagement
- Medical aid in dying requests — legal in some jurisdictions; requires specific protocol
- Do not conflate these. Do not avoid the question.
"I've sat with patients who were profoundly at peace and patients who were in spiritual agony — and from the outside, you couldn't always tell the difference. The ones in agony weren't always crying. Some of them were very quiet, very polite, very 'I'm fine.' You have to ask. You have to ask directly, you have to sit down, and you have to mean it when you do."
— Waldo, NP · Terminal2
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
Your loved one has a brain tumor called glioblastoma. It is the most common type of brain cancer in adults, and it is serious. The tumor is growing in the brain, and as it grows, it affects how your loved one thinks, speaks, moves, and acts. The changes you are seeing are caused by the tumor — not by choice. This guide is written for you, the family, to help you understand what is happening and what you can do.
What You May See
- Personality changes: Your loved one may say things that are out of character, become irritable, disinhibited, or emotionally flat. This is the brain tumor, not them choosing to behave this way.
- Memory and confusion: Forgetting names, getting lost in familiar places, repeating questions. This is the disease affecting the brain.
- Seizures: Sudden shaking, staring spells, or loss of consciousness. Your nurse will teach you what to do if this happens.
- Increasing sleepiness: Sleeping 16–20 hours a day as the disease progresses. This is normal and expected.
- Difficulty swallowing: Medications and food may become harder. Your nurse will adjust the medication route.
- Weakness on one side of the body: This is the tumor affecting the motor cortex. Falls become a risk.
How You Can Help
- Do not argue with confusion or personality changes: Redirect gently, stay calm. Remember this is the tumor, not your person choosing this.
- Keep the environment safe: Remove fall hazards, pad sharp corners if seizures are occurring, do not leave alone if seizure risk is high.
- Have the seizure emergency medication ready: Your nurse will show you how to use it. Call the nurse after a seizure, not 911 in most circumstances.
- Create connection through senses that remain: Music from their life, familiar scents, touch, familiar voices. The hearing often remains even when language fails.
- Let yourself grieve while they are still here: You are not disloyal for mourning. This grief has a name and it is real.
📞 Call the nurse immediately if you see:
Seizure lasting more than 5 minutes or cluster of seizures — administer emergency medication your nurse has prepared; call nurse. Sudden severe headache unlike prior headaches — possible hemorrhage, call nurse immediately. Sudden complete loss of ability to speak or respond — call nurse. Inability to be woken. You are overwhelmed and need support — that is always a reason to call.
🙏 You are experiencing a loss that has no clean name. The person you love is still here, and also not here in the way they were. Both of those things are true at the same time. What you are doing — staying, showing up, learning the seizure protocol, sitting in the silence when words are gone — is an act of love that most people will never fully understand. You are not alone in this. We are here with you.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
- 01The goals-of-care window closes. Have the conversation today if the patient has capacity. Do not wait. In GBM, next week may be too late and the family will be making decisions they were never prepared for. I have watched this happen dozens of times — the clinician who said "we'll talk about it next visit" and then the patient couldn't form sentences by the next visit. The cognitive window is real. It is short. Walk through it while it's open.
- 02Steroid taper is not optional to figure out. Get the dexamethasone dose right from day one. Too much causes Cushingoid state and psychiatric effects — the family watches their person swell, break out, become manic or paranoid, and they think the disease is doing it. Sometimes it's the drug. Too little causes rebound edema and acute crisis. The lowest effective dose is the target. Check it every visit. Document the reasoning. This is the most important medication management task in GBM hospice care.
- 03Tramadol is contraindicated. Full stop. If you inherit a GBM patient on tramadol from a prior provider, convert immediately to oxycodone IR. This is not a debatable clinical point — tramadol lowers seizure threshold through serotonergic mechanisms, and your GBM patient is already at 25–40% lifetime seizure risk. Document the conversion and the reason. Morphine or oxycodone. Not tramadol. Not ever.
- 04Personality change preparation saves families. The frontal lobe disinhibition, the temporal irritability, the steroid-induced emotional lability — name it before it happens. Sit the family down early and say: "The tumor may change how he talks to you, how he filters his words, how he controls his emotions. When that happens, it will feel personal. It's not. It's the tumor pressing on the part of the brain that handles all of that." The family who was briefed is not destroyed by it. The family who was not is.
- 05Seizure preparedness is a day-one obligation. Midazolam drawn, labeled, at the bedside, family trained. A breakthrough seizure at home without emergency medication available is a failure of clinical preparation, not a medical inevitability. Teach the family before the first seizure — positioning, timing, buccal midazolam administration, when to call hospice vs. 911. A seizure at 3 AM with a plan is scary but manageable. Without one, it's chaos.
- 06The ambiguous loss conversation. Families of GBM patients are grieving a living person. The wife who says "I know he's still here, but I've been mourning him for months" is not being dramatic — she is describing the defining psychological experience of GBM caregiving. Validate it by name. Give them permission to grieve while the patient is still breathing. It is not disloyal. It is honest. And it is the thing that lets them keep showing up day after day.
- 07Chaplain at enrollment, not at crisis. The spiritual dimension of cognitive loss and personality change is profound. The patient who can still articulate their faith and fears needs chaplain involvement now — not in the final days when language is gone. For patients of faith, losing the ability to pray, to read scripture, to connect with their faith community is a specific wound that demands specific attention. Don't leave this to the last week.
- 08Swallowing assessment at every visit. GBM causes dysphagia as the disease progresses — the brainstem and cortical swallowing centers are affected. Do not wait for a choking event to discover the patient can no longer swallow pills. Have the SQ conversion plan written before you need it. Know which medications have liquid formulations. Know when to switch to a fentanyl patch for stable pain. Plan the route conversion before the crisis, not during it.
- 09Caregiver burnout in GBM is among the highest of any hospice diagnosis. The 24-hour care burden combined with the grief of personality change combined with the uncertainty of seizure risk creates a caregiver in constant crisis. Studies using the Zarit Burden Interview consistently show GBM caregivers have higher burden scores than caregivers of any other cancer. Assess separately from the patient. Intervene early. Connect to respite before collapse — the hospice benefit includes up to 5 consecutive days of respite care, and it is chronically underutilized.
- 10The hearing often persists when everything else is gone. Speak to the patient in the final hours even when they are unresponsive. Tell the family to speak. Play the music from their life — the songs from their wedding, the hymns from their church, the album they played on repeat in college. Music reaches parts of the brain that language no longer can. This is not sentiment. This is neuroscience — the auditory cortex and limbic system often remain active well after higher cortical function is lost. Act accordingly. Be present. Say the things that need saying. Don't wait.
— Waldo, NP
References
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Ostrom QT, et al. CBTRUS Statistical Report: Primary Brain and Other CNS Tumors Diagnosed in the United States in 2016–2020. Neuro-Oncology. 2023;25(suppl 2):iv1–iv99.
2
Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
3
Koekkoek JAF, et al. Epilepsy in the end of life phase of brain tumor patients: a systematic review. Neuro-Oncol Pract. 2014;1(3):79–84.
4
Walbert T, Khan M. End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review. J Neurooncol. 2014;117(2):217–224.
5
Weller M, et al. Glioma. Nat Rev Dis Primers. 2015;1:15017.
6
Hegi ME, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.
7
Sizoo EM, et al. Issues in end of life care for patients with high-grade glioma. Eur J Cancer. 2010;46(6):1145–1150.
8
Lamborn KR, et al. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-Oncology. 2004;6(3):227–235.
9
Morita T, et al. Validity of the palliative prognostic index for estimating survival in terminally ill cancer patients. Ann Oncol. 2001;12(2):251–253.
10
Norden AD, et al. Antiepileptic drug therapy in patients with glioma. J Clin Oncol. 2010;28(12):2010–2016.
11
Newton HB, et al. Glucocorticoid use in neuro-oncology: an update. Brain Tumor Pathol. 2010;27(2):103–115.
12
Usery JB, et al. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol. 2010;99(2):251–260.
13
Villanueva V, et al. Lacosamide in daily clinical practice: treatment of focal epilepsy. Acta Neurol Scand Suppl. 2011;(191):16–27.
14
Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas. Epilepsia. 2013;54(Suppl 9):12–17.
15
Glantz MJ, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology. 2000;54(10):1886–1893.
16
McIntyre J, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366(9481):205–210.
17
Koekkoek JAF, et al. Antiepileptic drug withdrawal in glioma patients after their first seizure. J Neurooncol. 2016;129(3):583–590.
18
Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol. 2011;4(2):233–242.
19
Liu MM, Reidy AB, Saatee S, Collard CD. Perioperative steroid management: approaches based on current evidence. Anesthesiology. 2017;127(1):166–172.
20
Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: a report of 14 cases and a review of the literature. J Affect Disord. 1983;5(4):319–332.
21
Dropcho EJ, Soong SJ. Steroid-induced weakness in patients with primary brain tumors. Neurology. 1991;41(8):1235–1239.
22
Freifeld AG, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update. Clin Infect Dis. 2011;52(4):e56–e93.
23
Chinot OL, et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722.
24
Weitzner MA, et al. The relationship between neuropsychological functioning and quality of life in adult brain tumor patients. Psychooncology. 1996;5(2):96–103.
25
Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology. 1993;43(9):1678–1683.
26
Mannix K. Palliation of nausea and vomiting in malignancy. Clin Med (Lond). 2006;6(2):144–147.
27
Bhatt A, Bhattacharjee MB, Bhatt S. Acute management of elevated intracranial pressure. Semin Neurol. 2016;36(6):502–505.
28
Dickman A, Schneider J, Varga J. The Syringe Driver: Continuous Subcutaneous Infusions in Palliative Care. 3rd ed. Oxford University Press; 2011.
29
Gardner JS, Blough D, Drinkard CR, et al. Tramadol and seizures: a surveillance study in a managed care population. Pharmacotherapy. 2000;20(12):1423–1431.
30
Sampson EL, et al. Enteral tube feeding for older people with advanced dementia. Cochrane Database Syst Rev. 2009;(2):CD007209.
31
Sizoo EM, et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro-Oncology. 2010;12(11):1162–1166.
32
Boele FW, et al. Caregiver burden of glioma patients and their informal caregivers: a review of literature. CNS Oncol. 2013;2(2):157–168.
33
Sherwood PR, et al. Predictors of distress in caregivers of persons with a primary malignant brain tumor. Res Nurs Health. 2006;29(2):105–120.
34
Gofton TE, et al. End-of-life care in patients with primary malignant brain tumors. Can J Neurol Sci. 2012;39(5):599–606.
35
Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004;3(3):159–168.
36
Klein M, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas. Lancet. 2002;360(9343):1361–1368.
37
Taphoorn MJB, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005;6(12):937–944.
38
Cella DF, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–579.
39
Sizoo EM, et al. The end-of-life phase of high-grade glioma patients: dying with dignity? Oncologist. 2013;18(2):198–203.
40
Walbert T, et al. Integration of palliative care into the neuro-oncology practice: patterns and predictors. Neuro-Oncol Pract. 2014;1(1):3–10.
41
Delgado-Guay MO, et al. Spirituality, religiosity, and spiritual pain among caregivers of patients with advanced cancer. Am J Hosp Palliat Care. 2011;28(7):455–461.
42
Back AL, et al. Approaching difficult communication tasks in oncology. CA Cancer J Clin. 2005;55(3):164–177.
43
Lapointe BJ, Bhangoo R, Beaumont A. Surgical aspects of high-grade glioma. Cancer Treat Res. 2015;163:35–52.
44
Brown PD, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy. Neuro-Oncology. 2013;15(10):1429–1437.
45
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–1850.
46
Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology. 2021;23(8):1231–1251.
47
Reyes-Botero G, et al. Late effects of radiation on the central nervous system. Expert Rev Anticancer Ther. 2012;12(8):1043–1058.
48
Norden AD, et al. The role of bevacizumab in the management of patients with malignant brain tumors. J Neurooncol. 2016;128(3):381–389.
49
Grant R, Liang BC, Slattery J, et al. Chemotherapy response criteria in malignant glioma. Neurology. 1997;48(5):1336–1340.
50
Tran KR, et al. Corticosteroid use in neuro-oncology: report of a survey of current practice. Neuro-Oncol Pract. 2014;1(2):68–74.
51
Jordan K, et al. Antiemetic efficacy and tolerability of olanzapine versus metoclopramide. Support Care Cancer. 2015;23(5):1545–1553.
52
Cavers D, et al. Stroke, dysphagia, and enteral feeding: a qualitative study. Clin Rehabil. 2012;26(8):728–735.
53
Kaal EC, Vecht CJ. The management of brain edema in brain tumors. Curr Opin Oncol. 2004;16(6):593–600.
54
Fearon K, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. All PMIDs hyperlinked for independent verification. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.